ArticleMedicine2025
Short-term effects of rivaroxaban combined with aspirin in the treatment of lower limb arterial atherosclerosis occlusion with stent placement: A retrospective study.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study evaluates the short-term effects of rivaroxaban combined with aspirin in treating lower limb arterial atherosclerosis occlusion after stent placement. Between July 2018 and December 2022, 141 patients with lower limb arterial atherosclerosis occlusion underwent stent placement and were divided into 2 groups based on the different treatments documented in the cases. The clopidogrel group (n = 70) received clopidogrel sulfate plus aspirin, while the rivaroxaban group (n = 71) received rivaroxaban plus aspirin. Outcomes included 1-year patency rate, bleeding events, acute embolism, amputation rates, coagulation indicators, and thromboelastography (TEG) parameters. The 1-year patency rate at 6 months postoperatively was higher in the rivaroxaban group (92.96%) compared to the clopidogrel group (P < .05). Both groups showed increased activated partial thromboplastin time (APTT) and prothrombin time (PT) and decreased D-dimer (D-D) and fibrinogen (FIB) levels after 6 months (P < .05). APTT and PT were higher, while D-D and FIB were lower in the rivaroxaban group (P < .05). TEG parameters showed increased reaction time (R), clot formation time (K), and clot index (CI) and decreased alpha angle (α), maximum amplitude (MA), and thromboelastometry (G) in both groups at 6 months. R, K, and CI were higher, and α, MA, and G were lower in the rivaroxaban group (P < .05). Bleeding events were similar between groups (P > .05), with 1 embolism case in the rivaroxaban group vs 2 in the clopidogrel group. Rivaroxaban combined with aspirin post-stent placement improved vascular patency and anticoagulation outcomes without increasing bleeding risk, offering an effective treatment option for lower limb arterial atherosclerosis occlusion.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.